Nothing Special   »   [go: up one dir, main page]

BR9713866A - Composição farmacéutica - Google Patents

Composição farmacéutica

Info

Publication number
BR9713866A
BR9713866A BR9713866-5A BR9713866A BR9713866A BR 9713866 A BR9713866 A BR 9713866A BR 9713866 A BR9713866 A BR 9713866A BR 9713866 A BR9713866 A BR 9713866A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
surfactant
water
active substance
absorption characteristics
Prior art date
Application number
BR9713866-5A
Other languages
English (en)
Inventor
Takehisa Hata
Yuji Tokunaga
Sumihisa Kimura
Takeo Hirose
Satoshi Ueda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR9713866A publication Critical patent/BR9713866A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

''Composição farmacêutica'' compreendendo uma substância ativa insolúvel em água, surfactante(s) e veículo(s) sólido(s), que possui características melhores de dissolução e absorção oral.
BR9713866-5A 1996-12-06 1997-12-05 Composição farmacéutica BR9713866A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32661896 1996-12-06
PCT/JP1997/004452 WO1998024418A1 (fr) 1996-12-06 1997-12-05 Compositions medicinales

Publications (1)

Publication Number Publication Date
BR9713866A true BR9713866A (pt) 2000-03-14

Family

ID=18189823

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713866-5A BR9713866A (pt) 1996-12-06 1997-12-05 Composição farmacéutica

Country Status (17)

Country Link
US (1) US6346537B1 (pt)
EP (1) EP0943327B1 (pt)
JP (1) JP4284706B2 (pt)
KR (1) KR20000057242A (pt)
CN (1) CN1149979C (pt)
AR (1) AR008927A1 (pt)
AT (1) ATE367150T1 (pt)
AU (1) AU726451B2 (pt)
BR (1) BR9713866A (pt)
CA (1) CA2274485C (pt)
DE (1) DE69737936T2 (pt)
ES (1) ES2286835T3 (pt)
HU (1) HU228680B1 (pt)
RU (1) RU2197226C2 (pt)
TW (1) TW426516B (pt)
WO (1) WO1998024418A1 (pt)
ZA (1) ZA9710927B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138466A (en) 1998-03-26 2005-11-20 Fujisawa Pharmaceutical Co Sustained release formulations containing macrolide compounds
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
CZ20013209A3 (cs) * 1999-03-11 2001-12-12 Fujisawa Pharmaceutical Co., Ltd. Prostředek, obsahující liposomy
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DE60309472T2 (de) * 2002-06-28 2007-06-28 Speedel Pharma Ag Pharmazeutische formulierung mit einem nicht peptidischen renin-hemmer und surfactant
JP2007527383A (ja) * 2003-07-09 2007-09-27 チョン クン ダン ファーマスーティカル コーポレイション タクロリムス固体分散物
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
PT1663216E (pt) 2003-08-29 2012-02-14 Veloxis Pharmaceuticals As Dispersões sólidas que compreendem tacrolímus
PL1663216T3 (pl) 2003-08-29 2012-03-30 Veloxis Pharmaceuticals As Kompozycje o zmodyfikowanym uwalnianiu zawierające takrolimus
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
US7652364B2 (en) * 2005-12-21 2010-01-26 Teradata Us, Inc. Crossing conductive traces in a PCB
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US9044391B2 (en) * 2007-01-10 2015-06-02 Board Of Regents, The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
KR100868295B1 (ko) * 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
EP2167033B1 (en) 2007-05-30 2017-04-19 Veloxis Pharmaceuticals A/S Once daily oral dosage form comprising tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8222272B2 (en) * 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
CA2729948C (en) * 2008-07-08 2021-11-23 Lifecycle Pharma A/S Tacrolimus for improved treatment of transplant patients
CN104173356A (zh) * 2008-09-17 2014-12-03 Cj第一制糖株式会社 肝适能固态分散物、包括其的药的组成物以及其制备方法
TWI510238B (zh) 2010-02-17 2015-12-01 Lifecycle Pharma As 穩定化他克莫司（ｔａｃｒｏｌｉｍｕｓ）組合物
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN105663092A (zh) * 2016-03-03 2016-06-15 海南华益泰康药业有限公司 一种含有他克莫司固体分散体的缓释胶囊及其制备方法
WO2017205659A1 (en) * 2016-05-26 2017-11-30 Dermala Inc. Compositions and methods for treating acne vulgaris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DK0406791T3 (da) 1989-07-05 1995-03-27 Fujisawa Pharmaceutical Co Vandigt flydende præparat til ekstern anvendelse
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5817333A (en) 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
ATE183083T1 (de) 1992-11-18 1999-08-15 Fujisawa Pharmaceutical Co Pharmazeutische zubereitung mit verlängerter wirkung
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Also Published As

Publication number Publication date
ES2286835T3 (es) 2007-12-01
KR20000057242A (ko) 2000-09-15
HUP0000587A3 (en) 2001-12-28
WO1998024418A1 (fr) 1998-06-11
CA2274485A1 (en) 1998-06-11
EP0943327A4 (en) 2003-06-25
ATE367150T1 (de) 2007-08-15
CA2274485C (en) 2008-02-05
US6346537B1 (en) 2002-02-12
HUP0000587A1 (hu) 2000-09-28
ZA9710927B (en) 1998-06-15
JP4284706B2 (ja) 2009-06-24
HU228680B1 (en) 2013-05-28
CN1245424A (zh) 2000-02-23
DE69737936D1 (de) 2007-08-30
EP0943327B1 (en) 2007-07-18
AU5136998A (en) 1998-06-29
CN1149979C (zh) 2004-05-19
DE69737936T2 (de) 2007-12-06
EP0943327A1 (en) 1999-09-22
TW426516B (en) 2001-03-21
RU2197226C2 (ru) 2003-01-27
AR008927A1 (es) 2000-02-23
AU726451B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
BR9713866A (pt) Composição farmacéutica
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
NL300253I1 (nl) Contrastmiddel voor diagnostische beeldvorming metverlengde retentie in.
PT1010688E (pt) 2-fenil-1-(3,4-di-hidroxi-5-nitrofenil)-1-etanonas substituidas seu uso no tratamento de algumas perturbacoes do sistema nervoso central e periferico e formulacoes do sistema nervoso central e periferico e formulacoes farmaceuticas que as contem
DK0695172T3 (da) Fast præparat med hurtig frigørelse, dets fremstilling og dets anvendelse
FR2774909B1 (fr) Formulation pharmaceutique, solution de perfusion et composition lyophilisee comprenant une epothilone.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
WO1995030410A3 (en) Transdermal device for administration through de-epithelialized skin
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
DE69932510D1 (de) Vaskularisierungsinhibitoren
PT799046E (pt) Solucoes estaveis de 2-cloro-2'-desoxiadenosina
DE69711649D1 (de) P1, p4-dithio-p2,p3-monochloromethylen 5',5'''-diadenosin-p1,p4-tetraphosphat verwendet als anti-thrombose mittel
ATE307497T1 (de) Pharmazeutische zusammensetzung
BR9610930A (pt) Composição depilatória incluindo uma quantidade funcional de um agente tixoitrópico, e, uso da quantidade funcional de um agente tixotrópico.
PT984788E (pt) Composicoes farmaceuticas de peptidos com baixa solubilidade em meio fisiologico
IL140667A0 (en) Compositions containing at least one active substance having an influence on the levels of lipids in the blood
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
PA8454301A1 (es) Composiciones solubilizadas de sertralina
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
ATE306914T1 (de) Wässerige lösung zur behandlung von enteroclysis bei hepatischer enzephalopathie

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE INFRINGE O ART. 8O COMBINADO COM O ART. 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]